SOLIGENIX, INC. Revenue from Contract with Customer, Including Assessed Tax
SOLIGENIX, INC. (SNGX) reported Revenue from Contract with Customer, Including Assessed Tax of $33.35 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2021-11-12
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for the quarter ending 2021-03-31 was $33.35K, a 96.05% decline year-over-year.
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for the quarter ending 2020-12-31 was $285.71K, a 49.72% decline year-over-year.
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for fiscal 2020 was $1.93M, a 39.96% decline from fiscal 2019.
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for fiscal 2019 was $3.22M, a 18.91% decline from fiscal 2018.
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for fiscal 2018 was $3.97M, a 16.50% decline from fiscal 2017.
- SOLIGENIX, INC. revenue from contract with customer, including assessed tax for fiscal 2017 was $4.75M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $33.35K 10-Q · filed 2021-11-12 | $319.07K derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $33.35K 10-Q · filed 2021-08-13 | $319.07K derived: sum of 3 quarters · filed 2021-08-13 | $826.24K derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-03-31 | $33.35K 10-Q · filed 2021-05-18 | $319.07K derived: sum of 2 quarters · filed 2021-05-18 | $826.24K derived: sum of 3 quarters · filed 2021-11-12 | $1.12M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-12-31 | $285.71K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $792.89K derived: sum of 2 quarters · filed 2021-11-12 | $1.09M derived: sum of 3 quarters · filed 2021-11-12 | $1.93M 10-K · filed 2021-03-30 |
| 2020-09-30 | $507.17K 10-Q · filed 2021-11-12 | $799.63K derived: sum of 2 quarters · filed 2021-11-12 | $1.64M 10-Q · filed 2021-11-12 | $2.21M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $292.46K 10-Q · filed 2021-08-13 | $1.14M 10-Q · filed 2021-08-13 | $1.71M derived: sum of 3 quarters · filed 2021-08-13 | $2.65M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $845.18K 10-Q · filed 2021-05-18 | $1.41M derived: sum of 2 quarters · filed 2021-05-18 | $2.36M derived: sum of 3 quarters · filed 2021-05-18 | $3.42M derived: sum of 4 quarters · filed 2021-05-18 |
| 2019-12-31 | $568.22K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $1.52M derived: sum of 2 quarters · filed 2021-03-30 | $2.58M derived: sum of 3 quarters · filed 2021-03-30 | $3.22M 10-K · filed 2021-03-30 |
| 2019-09-30 | $946.98K 10-Q · filed 2020-11-12 | $2.01M derived: sum of 2 quarters · filed 2020-11-12 | $2.65M 10-Q · filed 2020-11-12 | $3.40M derived: sum of 4 quarters · filed 2020-11-12 |
| 2019-06-30 | $1.06M 10-Q · filed 2020-08-14 | $1.70M 10-Q · filed 2020-08-14 | $2.46M derived: sum of 3 quarters · filed 2020-08-14 | $3.52M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | $639.56K 10-Q · filed 2020-05-15 | $1.40M derived: sum of 2 quarters · filed 2020-05-15 | $2.46M derived: sum of 3 quarters · filed 2020-05-15 | $3.83M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $756.24K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $1.82M derived: sum of 2 quarters · filed 2020-03-30 | $3.19M derived: sum of 3 quarters · filed 2020-03-30 | $3.97M 10-K · filed 2020-03-30 |
| 2018-09-30 | $1.06M 10-Q · filed 2019-11-12 | $2.43M derived: sum of 2 quarters · filed 2019-11-12 | $3.21M 10-Q · filed 2019-11-12 | $4.24M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $1.37M 10-Q · filed 2019-08-13 | $2.14M 10-Q · filed 2019-08-13 | $3.18M derived: sum of 3 quarters · filed 2019-08-13 | $4.57M derived: sum of 4 quarters · filed 2019-08-13 |
| 2018-03-31 | $777.28K 10-Q · filed 2019-05-14 | $1.81M derived: sum of 2 quarters · filed 2019-05-14 | $3.20M derived: sum of 3 quarters · filed 2019-05-14 | $4.20M derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $2.43M derived: sum of 2 quarters · filed 2019-03-26 | $3.42M derived: sum of 3 quarters · filed 2019-03-26 | $4.75M 10-K · filed 2019-03-26 |
| 2017-09-30 | $1.40M 10-Q · filed 2018-11-09 | $2.39M derived: sum of 2 quarters · filed 2018-11-09 | $3.72M 10-Q · filed 2018-11-09 | |
| 2017-06-30 | $990.97K 10-Q · filed 2018-08-08 | $2.32M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |